Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Alpha Tau Medical Ltd. is a clinical-stage biotechnology company dedicated to the advancement and eventual commercialization of innovative cancer treatments. Their primary focus is on "Alpha DaRT" (Diffusing Alpha-Emitters Radiation Therapy), a novel approach designed to combat solid tumors. This therapeutic radiation technique is currently undergoing clinical evaluation for various solid malignancies, including skin, oral, pancreatic, and breast cancers, with development efforts primarily concentrated in Israel and the United States. Furthermore, Alpha DaRT is being explored in preclinical investigations for additional challenging cancers such as hepatic cell carcinoma, glioblastoma multiforme (a type of brain tumor), and lung cancer, among others. Established in 2015, the company maintains its headquarters in Jerusalem, Israel.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of DRTS is 13 and suggests 36% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase